Saturday, October 31, 2026

EUR/CHF Over 2% Up In The Last 21 Sessions

EUR/CHF Over 2% Up In The Last 21 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 2.03% for the last 21 sessions. At 09:06 EST on Thursday, 28 March, EUR/CHF (EURCHF) is $0.98.

EUR/CHF's yearly highs and lows, it's 8.162% up from its 52-week low and 2.232% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was 0.10%, 0.10%, and 0.23%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.52% (last week), 0.24% (last month), and 0.23% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • Eur/usd analysis: dollar remains strong - 26 March 2024. According to DailyForex on Tuesday, 26 March, "Technically, the EUR/USD currency pair is now trading below the 50-, 100- and 200-day moving averages, a clear indication that the trend is turning from positive to negative. ", "Commenting on the performance, Scotiabank analyst Shaun Osborne says the short-term technical for EUR/USD are "bearish... losses near the top of the euro's recent trading range have brought the spot price back to near the bottom end of the recent trading range."
  • Eur/usd forex signal: weakly bullish above $1.0832 - 26 March 2024. According to DailyForex on Tuesday, 26 March, "My previous EUR/USD signal on 12thMarchwas not triggered as the bullish price action took place below the support level which I had identified at $1.0914.", "In my previous analysis ofthe EUR/USD currency pairtwo weeks ago, I wrote that the real question seemed to be whether the $1.0900 area would hold now. "
  • Eur/usd struggles for a firm intraday direction, stuck in a range below mid-1.0800s. According to FXStreet on Tuesday, 26 March, "The EUR/USD pair struggles to capitalize on the previous day's goodish rebound from the 1.0800 mark, or a three-week low and oscillates in a narrow range during the Asian session on Tuesday. ", "This, along with the US bond yield and the broader risk sentiment, will drive demand for the safe-haven buck and provide some impetus to the EUR/USD pair. "
  • Eur/usd dips on buoyant US dollar, as ECB officials remain dovish. According to FXStreet on Tuesday, 26 March, "Following the data, the fundamentals surrounding the EUR/USD pair remained unchanged. ", "The EUR/USD was unable to achieve a decisive break of the 200-day moving average (DMA), opening the door to challenging the 1.0800 mark. "

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com